CN1358534A - Compound medicine for treating bronchial asthma and preparation process - Google Patents
Compound medicine for treating bronchial asthma and preparation process Download PDFInfo
- Publication number
- CN1358534A CN1358534A CN 01135286 CN01135286A CN1358534A CN 1358534 A CN1358534 A CN 1358534A CN 01135286 CN01135286 CN 01135286 CN 01135286 A CN01135286 A CN 01135286A CN 1358534 A CN1358534 A CN 1358534A
- Authority
- CN
- China
- Prior art keywords
- bronchial asthma
- medicine
- treatment
- asthma
- aminophylline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003556 aminophylline Drugs 0.000 claims abstract description 12
- 229960001117 clenbuterol Drugs 0.000 claims abstract description 9
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 9
- FDXKCOBAFGSMDJ-UHFFFAOYSA-N 1-(5,5-dioxophenothiazin-10-yl)-n,n-dimethylpropan-2-amine Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3S(=O)(=O)C2=C1 FDXKCOBAFGSMDJ-UHFFFAOYSA-N 0.000 claims description 7
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 6
- 229960003291 chlorphenamine Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 235000014666 liquid concentrate Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 2
- 244000003416 Asparagus officinalis Species 0.000 abstract 2
- 235000005340 Asparagus officinalis Nutrition 0.000 abstract 2
- 241000202807 Glycyrrhiza Species 0.000 abstract 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 2
- 241000249864 Tussilago Species 0.000 abstract 2
- 229940010454 licorice Drugs 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 238000002791 soaking Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 206010011224 Cough Diseases 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 210000000621 bronchi Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 240000000377 Tussilago farfara Species 0.000 description 2
- 235000004869 Tussilago farfara Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 238000002555 auscultation Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RJGBSYZFOCAGQY-UHFFFAOYSA-N 5-methoxyfuran-2-carbaldehyde Chemical compound COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001645732 Bacillus albus Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000011276 addition treatment Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a compound medicine for curing bronchial asthma prepared by using several medicine. It is made up dioxypromazine, clenbuterol, aminophylline, asparagus, tussilago, licorice and chlotrimeton according to a certain mixing ratio. Its preparation method includes the following steps: soaking asparagus, tussilago and licorice, decocting and filtering to obtain liquid medicine, concentrating and fully mixing it with the raw materials of dioxypromaxine, clenbuterol, aminophylline and chlotrimeton, drying and making it into capsule or talbet with a certain weight. Said invention is obvious in therapeutic effect, and high in cure rate, can be extensively used for curing bronchial asthma.
Description
The present invention relates to a kind of medicine for the treatment of bronchial asthma and preparation method thereof, specifically a kind of is the compound medicine and preparation method thereof of the treatment bronchial asthma that forms of preparation of raw material by multiple medications.
Bronchial asthma is a kind of a kind of bronchus reflection property enhancing that causes because of anaphylactogen or other factors, cause bronchial muscular spasm, mucosa swelling, secretions increases, the bronchus tube chamber is narrow, it is the disease of feature that ictal dyspnea and asthmatic breath sounds are arranged clinically, and morbidity season is mainly in autumn and winter, and take second place spring.Primary disease shows effect repeatedly, and delay is difficult, and particularly the morbidity of north cold area and middle-aged and elderly people is very general and serious, and patient's physical and mental health is brought very big harm.Modern medicine study thinks that irritated and autonomic nervous dysfunction is two principal elements of bronchial asthma morbidity, and the outbreak repeatedly of bronchial asthma is caused by many risk factors, the one, and respiratory tract infection.Mainly cause, as rhinovirus, respiratory syncytial virus, influenza virus etc. by virus.The patient due to illness substance allergy or inflammatory stimulus fan compose oneself through, infect making bronchial mucosa inflammation edema, cellular infiltration and secretions increase, increase the weight of asthma; The 2nd, anaphylactogen and chemical factors.Can be after patient's contact allergy is former by the morbidity of anaphylaxis factor pathogeny, some nonantigenic chemical factors are as sucking cold air, dust, atmospheric pollution, smoking even cooking gas, stimulate intrabronchial sensor, excited vagus causes asthma attack; The 3rd, function of five internal organs weakens.Strain, decline cause heart blood supply not strong, deficiency of heart-QI, and lung expansion slows down, the taste QI-mass water that stagnates, defecation is not smooth, and the vivotoxin poisonous substance can not in time be discharged, initiation asthma; The 4th, climate change.Frequent and the many cataclysms of autumn and winter climate change, easy ill toxicity upper respiratory tract infection, air pressure is low can to make pollen, harmfulness dust, irritative gas etc. be gathered in ground, and concentration increases, and sucks easily, all can bring out asthma; The 5th, Nervous and Mental Factors.Excited, trained reflex all can bring out bronchial asthma.
At present, a lot of to the THE TREATMENT OF BRONCHIAL ASTHMA method both at home and abroad.Its Therapeutic Principle removes the cause of disease, control of seizures and prevention of recurrence.Aspect control of seizures, to light, moderate outbreak, mainly be to carry out bronchus with theophylline class medicine such as aminophylline, adrenin such as salbutamol, adrenal cortex saccharide hormone etc. to separate stem, eliminate the phlegm, use the antibiotic medicine control infection with medicines such as ammonium chloride, potassium iodide; Asthma is continued the outbreak state, mainly is to rely on oxygen uptake, intravenous drip aminophylline, hydrocortisone, antibiotic etc. to treat.Aspect prevention of recurrence, mainly be to take disodium cromoglycate, injection asthmatic vaccine or nuclear cheese and adopt desensitization therapy etc.Domestic also a small amount of in addition treatment by Chinese herbs bronchial asthma that adopts.But existing therapy exists, and therapeutic effect is undesirable, easily outbreak repeatedly, toxic and side effects is big, treatment time is long, therapeutic process is complicated, the patient is to shortcomings such as drug dependence are strong, does not reach the curative effect of thorough healing bronchial asthma.
Purpose of the present invention just is to provide that a kind of therapeutic effect is remarkable, cure rate is high, the compound medicine of the treatment bronchial asthma of non-evident effect, instant effect, nothing recurrence, taking convenience.
The present invention is achieved in that
A kind of compound medicine for the treatment of bronchial asthma, it is that various composition medicines by the following weight proportioning are the medicine that raw material is made, wherein:
Dioxopromethazine: 3-12 part; Clenbuterol: 0.02-0.08 part; Aminophylline: 50-400 part; Radix Asparagi: 5000-30000 part; Flos Farfarae: 5000-30000 part; Radix Glycyrrhizae: 5000-15000 part; Chlorphenamine: 2-6 part.
The best by weight enforcement proportioning of medicine of the present invention is: get 10 parts in dioxopromethazine, 0.04 part of clenbuterol, 200 parts of aminophyllines, 14000 parts of Radix Asparagi, 16000 parts of Flos Farfaraees, 8000 parts in Radix Glycyrrhizae, 4 parts of chlorphenamines.BATIANMEN winter, Flos Farfarae, Radix Glycyrrhizae soak, decoct and filtering residue after medicinal liquid concentrate, then with the abundant combination dryings of crude drug such as dioxopromethazine, clenbuterol, aminophylline, chlorphenamine after, be made into 260 milligrams every the capsule or the tabloid of constant weight.Each 2 or several pieces during use, every day three times, 14 days is a course of treatment, serve on two courses of treatment, can effectively treat bronchial asthma.
It is bronchial muscular spasm and the pathogenetic understanding and the Therapeutic Principle that cause to bronchial asthma morbidity that solution of the present invention is based on modern medicine study, find with reference to modern medicine study, select to contain the Western medicine of various active ingredients and Chinese herbal medicine extract and formed compound medicine, comprehensively play bronchus spasmolysis, eliminate the phlegm, control infection, prevention of recurrence and alleviate respiratory tract infection, anaphylactogen, chemical factors, climate change, Nervous and Mental Factors etc. to the bringing out of bronchial asthma, thereby reach the purpose of treatment, control and prevention bronchial asthma attack.
Modern pharmacology studies have shown that:
1, dioxopromethazine.This product is the derivant of promethazine, has stronger central antitussive effect and relieving asthma to eliminate the phlegm antihistamine, local anesthesia, releasing smooth muscle spasm and antiinflammation.Can cooperate other medicines treatment bronchial asthma.
2, clenbuterol.This product acts on the beta 2 receptor of bronchial smooth muscle and strengthens ciliary movement, and the promotion sputum is discharged and relievingd asthma.Can cooperate other medicines treatment bronchial asthma.
3, aminophylline.Aminophylline is the complex of theophylline and ethylenediamine, and it can destroy the phosphodiesterase of phosphoric acid gland glycoside (CAMP) by inhibition, thereby increases the content of CAMP in cell, and makes the sliding muscle relaxation of bronchus sheep.Alleviations such as mainly curing bronchial asthma, asthmatic bronchitis, the obstructive emphysema symptom of panting.Also can be used for treating the asthma of heart failure.
4, Flos Farfarae.Dry flower for the feverfew coltsfoot.Acrid in the mouth, little sweet, warm in nature, return lung meridian.Nourishing the lung to keep the adverse QI downward, preventing phlegm from forming and stopping coughing.Cure mainly that new chronic cough is coughed, asthma, abundant expectoration, chronic cough spitting of blood etc.
Modern medicine study proves: Flos Farfarae contains alkaloid (Flos Farfarae alkali etc.), coltsfoot alcohol, plant sterol, tarachrome, tannin, aminoacid and inorganic elements etc.Pharmacological research shows that this product has antitussive, eliminates the phlegm, relievings asthma, breathes excited, the effect of antiplatelet activity factor, the effect that rises blood pressure in addition in addition.
5, Radix Asparagi.Tuber for the liliaceous plant Radix Asparagi.Sweet in the mouth, hardship, property Great Cold.Return lung, kidney channel.Lung heat clearing pathogenic fire reducing, nourshing Yin and drynsessmoistening prescription.Cure mainly fever due to yin deficiency, the cough haematemesis, consumptive lung disease, lung abscess, laryngopharynx swelling and pain, quench one's thirst, constipation.
Modern medicine study proves: Radix Asparagi contains asparagine (agedoite), is stained with liquid matter, cupreol, 5-methoxy furfural and steroid saponin.Pharmacological research shows that this product has stronger antibacterial action, the decoct in vitro tests, and anthrax bacillus, first type and hemolytic master are connected coccus, Diplococcus pneumoniae, staphylococcus aureus, bacillus albus, bacillus subtilis, bacillus pyocyaneus etc. inhibitory action.Contained Radix Asparagi have cough-relieving, antiasthmatic effect; Cupreol has antitussive, phlegm-dispelling functions.
6, Radix Glycyrrhizae extract (Chinese herbal medicine).Property is put down, and sweet in the mouth is nontoxic.Can promote the usefulness of other medicines, remove toxin in the medicine, relieving convulsion, refresh oneself expelling phlegm for arresting cough.
7, chlorphenamine.This product is applicable to the antihistaminic symptom.As: urticaria, contracting property of blood vessel neighbour rhinitis, vasodilation, pollinosis, contact dermatitis and because caused allergic conditions such as insect bite stimulation, drug reaction or food.
In sum, in the medicine of the present invention, Chinese medicinal ingredients has antiinflammatory, antiallergic action and antibiotic, spasmolytic, relaxing smooth muscle effect, and western medicine composition can be alleviated bronchial muscular spasm and bronchial mucosa congestion and edema, the bronchus bore is enlarged, remove asthma.Medicine Chinese medicine and western medicine of the present invention combination has the antiinflammatory spasmolytic, an effect such as eliminate the phlegm of relievining asthma.Effect is all multifactor comprehensive functions to medicine of the present invention to THE TREATMENT OF BRONCHIAL ASTHMA, at the pathogeny of bronchial asthma, by different action pathway, comprehensively brings into play the length of each pharmaceutical compositions, reaches treating both the principal and secondary aspects of a disease, eliminates the purpose of bronchial asthma attack.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, to select clinical single-dose thing commonly used and Chinese herbal medicine for use be raw material in the present invention, and each component maximum level is no more than the pharmacopeia regulation, and is safe in utilization, and do not have incompatibility, scientific formulation each other.Utilize the comprehensive function treatment bronchial asthma of multiple single-dose and Chinese herbal medicine, useful effect is coordinated and non-evident effect mutually, and with low cost.
2, the present invention has avoided the infringement to human body such as non-steroidal drug, and is safe and reliable, taking convenience.
3, medicine of the present invention can use separately, also can cooperate at patient's state of an illness and take other drug; Can effectively increase medicine power of the present invention, improve patient's mental status, improve the quality of living.
4, the total effective rate of medicine of the present invention reaches more than 94.8%.
5, to the bronchial asthma patient of Drug therapy of the present invention, follow up a case by regular visits to 1-3, do not have any recurrence.
For showing medicine of the present invention to the THE TREATMENT OF BRONCHIAL ASTHMA effect, medicine of the present invention and routine medication bronchial asthma have been carried out the clinical treatment contrast test, it specifically tests as follows.
Diagnostic criteria: bronchial asthma is divided three kinds of exogenous (anaphylactic type asthma), endogenous (infection type asthma) and Combination.Premonitory symptoms such as cough, uncomfortable in chest or continuous sneeze are often arranged before the outbreak.Dyspnea, asthma and excessive phlegm appear in stage of attack, physical examination, and much fuller chest is, and chest wall movement is limited, and percussion is hyperresonant note, and border of cardiac dullness dwindles, and liver dullness circle moves down, and auscultation two lungs are covered with the asthma sound.Outbreak later stage accompanying infection person can have moist rale, and purple water from washing rice appears in severe patient.The outbreak persistent state, dyspnea increases the weight of, and mouth breathing, purple water from washing rice, dripping sweat, pale complexion appear, the extremity fault is cold, pulsation is fast, respiratory failure occurs when serious, auscultation has obvious wheezing sound.
Test grouping: choose complete data patient 169 examples before and after the treatment, all cases all meet above-mentioned bronchial asthma diagnostic criteria, selected case age 11-62 year, average 42.5 years old, medical history 0.5～19 year, average 8.6 years.By age, sex, medical history, the state of an illness, be divided into medication therapy groups of the present invention and conventional medicine matched group at random, wherein 96 examples are organized in treatment, matched group 73 examples, two groups of various diagnostic observation indexs relatively all do not have significant difference.
Therapeutic Method: medication therapy groups of the present invention is taken 260 milligrams/of medicine capsules of the present invention (or tablet of constant weight), each 2 or several pieces, and every day 3 times, 14 days is a course of treatment.After taking a course of treatment, the pulmonary respiration amount increases, and blood pressure is normal substantially, and sleep is better, and appetite is preferable; Expectorant, breathe heavily, cough disease and disappear substantially.Obey a course of treatment again, various transference cures do not have recurrence substantially.
The routine medication matched group is taken aminophylline 0.1-0.2g/ time, and every day 3 times, 14 days is a course of treatment, takes two courses of treatment continuously.
Curative effect determinate standard: finish back or the disappearance of drug administration process mesobronchus asthma two courses of treatment, and no recidivist is for curing in 3 months; If the recurrence of 3 months entobronchus asthma, take again after a course of treatment bronchial asthma promptly disappearance person be produce effects; After finished two courses of treatment, bronchial asthma alleviated or disappears, when being arranged, inducement easily shows effect, but the attack times minimizing, the persistent period shortens and does not influence work and give birth to the reviver for effective; After finishing two courses of treatment, do not alleviate but still show effect frequently though bronchial asthma has to alleviate or have, and to influence work and give birth to the reviver be invalid.
Therapeutic outcome: in the treatment group, cure 29 examples, account for 30.2%; Produce effects 41 examples account for 42.7%; Effective 21 examples account for 21.9%; Invalid 5 examples account for 5.2%; Total effective rate 94.8%.In the matched group, cure 14 examples, account for 19.2%; Produce effects 22 examples account for 30%; Effective 12 examples account for 16.4%; Invalid 2.25 examples account for 34.2%, total effective rate 65.8%.
Picked at random 4 examples are described further effect of drugs of the present invention from above-mentioned test.
Example 1: Xing Liansheng, the man, 62 years old, Heilongjiang Province's huge rock people from county, cough, asthma are more than 3 years, and see the doctor for treatment in many places, i.e. slowly recurrence after the drug withdrawal.Take medicine of the present invention after two courses of treatment, after drug withdrawal in May, 2000, recurrence so far.
Example 2: Zhang Guanghou, the man, 57 years old, Yanggu County ten Wu Liyuan people from town suffered from uncomfortable in chest, cough, asthma, and inappetence, weak all over was had a surplus in 2 years, took medicine of the present invention after two courses of treatment, and above-mentioned symptom all disappears, after drug withdrawal in October, 2000, recurrence so far.
Example 3: Zhu Li, the woman, 26 years old, Taiqian County grandson's mouth village people suffered from bronchial asthma 8 years, took medicine of the present invention and fully recovered after two courses of treatment, followed up a case by regular visits to not recurrence in 3 years.
Example 4: Yang Fenghua, the woman, 46 years old, Acheng, Yanggu County people from town suffered from bronchial asthma 4 years, took medicine of the present invention after two courses of treatment, and transference cure is followed up a case by regular visits to and was not had recurrence in 2 years.
Claims (3)
1, a kind of compound medicine for the treatment of bronchial asthma is characterized in that: it is that various composition medicines by the following weight proportioning are the compound medicine that raw material is made.
Dioxopromethazine: 3-12 part; Clenbuterol: 0.02-0.08 part; Aminophylline: 50-400 part; Radix Asparagi: 5000-30000 part; Flos Farfarae: 5000-30000 part; Radix Glycyrrhizae: 5000-15000 part; Chlorphenamine: 2-6 part.
2, the compound medicine of treatment bronchial asthma as claimed in claim is characterized in that: wherein the optimum weight proportioning of each raw material composition is:
Dioxopromethazine: 10 parts; Clenbuterol: 0.04 part; Aminophylline: 200 parts; Radix Asparagi: 14000 parts; Flos Farfarae: 16000 parts; Radix Glycyrrhizae: 8000 parts; Chlorphenamine: 4 parts.
3, the preparation method of the compound medicine of treatment bronchial asthma as claimed in claim 1 or 2, it is characterized in that: the Radix Asparagi of constant weight proportioning, Flos Farfarae, Radix Glycyrrhizae are soaked, decoct and filtering residue after medicinal liquid concentrate, then with the abundant combination dryings of crude drug such as the dioxopromethazine of constant weight proportioning, clenbuterol, aminophylline, chlorphenamine after, the capsule or the tablet that are made into constant weight promptly are prepared from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01135286 CN1358534A (en) | 2001-12-14 | 2001-12-14 | Compound medicine for treating bronchial asthma and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01135286 CN1358534A (en) | 2001-12-14 | 2001-12-14 | Compound medicine for treating bronchial asthma and preparation process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1358534A true CN1358534A (en) | 2002-07-17 |
Family
ID=4673095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01135286 Pending CN1358534A (en) | 2001-12-14 | 2001-12-14 | Compound medicine for treating bronchial asthma and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1358534A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101023953B (en) * | 2006-07-24 | 2010-05-12 | 南开大学 | Composition for treating bronchial asthma |
| CN103083524A (en) * | 2011-10-27 | 2013-05-08 | 天津生机集团股份有限公司 | Traditional Chinese medicine granules used for treating chicken aspergillosis, and preparation method thereof |
| CN106377653A (en) * | 2016-08-22 | 2017-02-08 | 吴斌 | A traditional Chinese medicine and western medicine composition for treating bronchial asthma caused by respiratory tract infection and a preparing method thereof |
-
2001
- 2001-12-14 CN CN 01135286 patent/CN1358534A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101023953B (en) * | 2006-07-24 | 2010-05-12 | 南开大学 | Composition for treating bronchial asthma |
| CN103083524A (en) * | 2011-10-27 | 2013-05-08 | 天津生机集团股份有限公司 | Traditional Chinese medicine granules used for treating chicken aspergillosis, and preparation method thereof |
| CN106377653A (en) * | 2016-08-22 | 2017-02-08 | 吴斌 | A traditional Chinese medicine and western medicine composition for treating bronchial asthma caused by respiratory tract infection and a preparing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671867A (en) | Traditional Chinese medicine composition for treating coronavirus pneumonia cough | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN102772650A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CN104116979A (en) | Medicinal liquor for treating phthisis and preparation method thereof | |
| CN101884727B (en) | Traditional Chinese medicine for treating rhinitis | |
| CN103751349B (en) | Traditional Chinese medicine composition for treating rhinitis and preparation method of composition | |
| CN1358534A (en) | Compound medicine for treating bronchial asthma and preparation process | |
| CN111494520A (en) | Medicine for treating rhinitis and preparation method and application thereof | |
| CN105250385A (en) | Nasal drops for treating infant nasal obstruction | |
| CN101129755A (en) | Orally taken traditional Chinese medicine composition for treating asthma | |
| CN1660256A (en) | A medicine for treating cough caused by upper respiratory tract inflammation | |
| CN1410105A (en) | Zibei Cough stopping granules and its preparation method | |
| CN1742912A (en) | Medicine for treating and preventing chronic obstractive pneumonia | |
| CN101181448A (en) | Oral administration proprietary Chinese medicine for curing facial palsy | |
| CN101199607A (en) | Nose kang tea | |
| CN105796746B (en) | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection | |
| CN117959357B (en) | A traditional Chinese medicine composition for treating diabetes and its preparation method and application | |
| CN108452213A (en) | A kind of Chinese medicine for treating rhinitis composition, Chinese medicine preparation and preparation method thereof | |
| CN101112602B (en) | Medicine for treating pharyngitis and method for preparing the same | |
| CN107669764A (en) | Pharmaceutical composition of combination therapy of Chinese and western bronchitis and preparation method thereof | |
| CN108261523A (en) | A kind of Chinese medicine composition and method for treating allergic rhinitis | |
| CN1096447A (en) | Health mask specially for tracheitis patient and pharmaceutical formulation thereof | |
| CN107029058A (en) | A kind of Chinese medicine composition for treating chronic pharyngitis | |
| CN104189610A (en) | Traditional Chinese medicine composition for treating bronchitis | |
| CN105381351A (en) | Traditional Chinese medicine for treating infantile asthma caused by lung qi obstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |